News

Net profit of Alembic Pharmaceuticals rose 12.11% to Rs 173.07 crore in the quarter ended June 2026 as against Rs 154.38 crore during the previous quarter ended June 2025. Sales rose 25.66% to Rs 2149.77 crore in the quarter ended June 2026 as against Rs 1710.72 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2149.771710.72 26 OPM %15.4416.42 - PBDT319.57263.88 21 PBT221.86190.11 17 NP173.07154.38 12 Powered by Capital Market - Live News

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg and 2 mg, have an estimated market size of US$ 100 million for twelve months ending March 2026 according to IQVIA.

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Alembic Pharmaceuticals announced that the 16th Annual General Meeting(AGM) of the company will be held on 5 August 2026.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC. Dapsone Gel is indicated for the topical treatment of acne vulgaris. Refer label for a detailed indication. Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA.